Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation
Shinsaku Imashuku,1 Naoko Kudo,1 Kagekatsu Kubo,1 Katsuyasu Saigo,1 Nanako Okuno,2 Kaoru Tohyama21Division of Hematology, Takasago-seibu Hospital, Takasago, Japan; 2Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, JapanBackground: Acquired hemophilia A is rarely found in associ...
Main Authors: | Okuno N, Tohyama K, Kubo K, Saigo K, Imashuku S, Kudo N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-12-01
|
Series: | Journal of Blood Medicine |
Online Access: | http://www.dovepress.com/rituximab-for-managing-acquired-hemophilia-a-in-a-case-of-chronic-neut-a11682 |
Similar Items
-
Acquired Hemophilia A successfully treated with rituximab
by: Giovanni D'Arena, et al.
Published: (2015-02-01) -
Management of Acquired Hemophilia A in Elderly Patients
by: Tomoya Yamaguchi, et al.
Published: (2018-01-01) -
JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-12-01) -
JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-10-01) -
SOCS3 degradation expedites the JAK2 signaling in the JAK2 V617F Tyrosine Kinase mutated cells
by: Yu-Chieh Lin, et al.
Published: (2007)